Today’s interims highlight the solid clinical development made during the year, and we expect value-crating interim data readouts from both lead candidates, Blautix and MRx0518, within the next six calendar months. We continue to believe 4D Pharma is set apart as a developer of live biotherapeutics and we reiterate our positive stance on 4D Pharma.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interims sets out near-term data catalysts
- Published:
30 Sep 2019 -
Author:
Edward Thomason -
Pages:
3
Today’s interims highlight the solid clinical development made during the year, and we expect value-crating interim data readouts from both lead candidates, Blautix and MRx0518, within the next six calendar months. We continue to believe 4D Pharma is set apart as a developer of live biotherapeutics and we reiterate our positive stance on 4D Pharma.